# HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma

> **NCT04668768** · PHASE2 · SUSPENDED · sponsor: **Fox Chase Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Glucarpidase

## Key facts

- **NCT ID:** NCT04668768
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-04-16
- **Primary completion:** 2024-12
- **Final completion:** 2025-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** To be terminated due to slow accrual, patient still in follow up
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04668768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04668768, "HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04668768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*